These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34984740)

  • 1. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
    Matthews A; Stanway S; Farmer RE; Strongman H; Thomas S; Lyon AR; Smeeth L; Bhaskaran K
    BMJ; 2018 Oct; 363():k3845. PubMed ID: 30297439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis.
    Yoo JJ; Jung EA; Kim Z; Kim BY
    Curr Oncol; 2023 Feb; 30(2):1831-1843. PubMed ID: 36826103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
    Faiz AS; Guo S; Kaveney A; Philipp CS
    Blood Coagul Fibrinolysis; 2021 Sep; 32(6):373-381. PubMed ID: 33973894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer.
    Alfaris I; Asselah J; Aziz H; Bouganim N; Mousavi N
    Curr Atheroscler Rep; 2023 Apr; 25(4):145-154. PubMed ID: 36848014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
    Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
    Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
    Chlebowski RT; Haque R; Hedlin H; Col N; Paskett E; Manson JE; Kubo JT; Johnson KC; Wactawski-Wende J; Pan K; Anderson G
    Breast Cancer Res Treat; 2015 Dec; 154(3):609-16. PubMed ID: 26602222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
    Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
    Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
    Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
    Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
    Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
    Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
    Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
    Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
    Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
    Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L
    Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.